Mucopolysaccharidosis (MPS) physical symptom score: Development, reliability, and validity

Research output: Chapter in Book/Report/Conference proceedingOther chapter contribution

3 Citations (Scopus)

Abstract

Objectives: We quantified medical signs and symptoms to construct the Physical Symptom Score (PSS) for use in research to assess somatic disease burden in mucopolysaccharidoses (MPS) to track disease and monitor treatments. We examined scoring reliability, its concurrent validity with other measures, and relationship to age in MPS type I. Methods: Fifty-four patients with MPS I (36 with Hurler syndrome treated with hematopoietic cell transplant and 18 with attenuated MPS I treated with enzyme replacement therapy), ages 5 to 18 years, were seen longitudinally over 5 years. The summation of frequency and severity of signs of specific organ involvement, surgeries, and hydrocephalus drawn from medical histories comprise the PSS. We examined relationship to age and to daily living skills (DLS) from the Vineland Adaptive Behavior Scale and physical quality of life from the Child Health Questionnaire (CHQ) for each group. Results: The PSS was associated with age in both groups, indicating increase in disease burden over time. The PSS was significantly negatively associated with DLS (r = −0.48) and CHQ (r = −0.55) in the attenuated MPS I but not in the Hurler group. Conclusions: The association of somatic disease burden with physical quality of life and ability to carry out daily living skills suggests that the PSS will be useful in the measurement of disease and treatment effects in the attenuated MPS I group. Earlier treatment with transplant and differing parental expectations are possible explanations for its lack of association with other outcomes necessitating an adaptation for Hurler syndrome in the future.

Original languageEnglish (US)
Title of host publicationJIMD Reports
PublisherSpringer
Pages61-68
Number of pages8
DOIs
StatePublished - Jan 1 2016

Publication series

NameJIMD Reports
Volume26
ISSN (Print)2192-8304
ISSN (Electronic)2192-8312

Fingerprint

Mucopolysaccharidoses
Mucopolysaccharidosis I
Reproducibility of Results
Transplants
Health
Quality of Life
Enzyme Replacement Therapy
Surgery
Aptitude
Psychological Adaptation
Hydrocephalus
Signs and Symptoms
Therapeutics
Enzymes
Research

Keywords

  • Carpal tunnel syndrome
  • Disease burden
  • Enzyme replacement therapy
  • Hematopoietic cell transplant
  • Shunt placement

Cite this

Mucopolysaccharidosis (MPS) physical symptom score : Development, reliability, and validity. / Ahmed, A.; Rudser, K.; Kunin-batson, A.; Delaney, Kathleen; Whitley, C.; Shapiro, E.

JIMD Reports. Springer, 2016. p. 61-68 Chapter 485 (JIMD Reports; Vol. 26).

Research output: Chapter in Book/Report/Conference proceedingOther chapter contribution

@inbook{29386dde0cae4f52ab57274bc366e8a8,
title = "Mucopolysaccharidosis (MPS) physical symptom score: Development, reliability, and validity",
abstract = "Objectives: We quantified medical signs and symptoms to construct the Physical Symptom Score (PSS) for use in research to assess somatic disease burden in mucopolysaccharidoses (MPS) to track disease and monitor treatments. We examined scoring reliability, its concurrent validity with other measures, and relationship to age in MPS type I. Methods: Fifty-four patients with MPS I (36 with Hurler syndrome treated with hematopoietic cell transplant and 18 with attenuated MPS I treated with enzyme replacement therapy), ages 5 to 18 years, were seen longitudinally over 5 years. The summation of frequency and severity of signs of specific organ involvement, surgeries, and hydrocephalus drawn from medical histories comprise the PSS. We examined relationship to age and to daily living skills (DLS) from the Vineland Adaptive Behavior Scale and physical quality of life from the Child Health Questionnaire (CHQ) for each group. Results: The PSS was associated with age in both groups, indicating increase in disease burden over time. The PSS was significantly negatively associated with DLS (r = −0.48) and CHQ (r = −0.55) in the attenuated MPS I but not in the Hurler group. Conclusions: The association of somatic disease burden with physical quality of life and ability to carry out daily living skills suggests that the PSS will be useful in the measurement of disease and treatment effects in the attenuated MPS I group. Earlier treatment with transplant and differing parental expectations are possible explanations for its lack of association with other outcomes necessitating an adaptation for Hurler syndrome in the future.",
keywords = "Carpal tunnel syndrome, Disease burden, Enzyme replacement therapy, Hematopoietic cell transplant, Shunt placement",
author = "A. Ahmed and K. Rudser and A. Kunin-batson and Kathleen Delaney and C. Whitley and E. Shapiro",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/8904_2015_485",
language = "English (US)",
series = "JIMD Reports",
publisher = "Springer",
pages = "61--68",
booktitle = "JIMD Reports",

}

TY - CHAP

T1 - Mucopolysaccharidosis (MPS) physical symptom score

T2 - Development, reliability, and validity

AU - Ahmed, A.

AU - Rudser, K.

AU - Kunin-batson, A.

AU - Delaney, Kathleen

AU - Whitley, C.

AU - Shapiro, E.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objectives: We quantified medical signs and symptoms to construct the Physical Symptom Score (PSS) for use in research to assess somatic disease burden in mucopolysaccharidoses (MPS) to track disease and monitor treatments. We examined scoring reliability, its concurrent validity with other measures, and relationship to age in MPS type I. Methods: Fifty-four patients with MPS I (36 with Hurler syndrome treated with hematopoietic cell transplant and 18 with attenuated MPS I treated with enzyme replacement therapy), ages 5 to 18 years, were seen longitudinally over 5 years. The summation of frequency and severity of signs of specific organ involvement, surgeries, and hydrocephalus drawn from medical histories comprise the PSS. We examined relationship to age and to daily living skills (DLS) from the Vineland Adaptive Behavior Scale and physical quality of life from the Child Health Questionnaire (CHQ) for each group. Results: The PSS was associated with age in both groups, indicating increase in disease burden over time. The PSS was significantly negatively associated with DLS (r = −0.48) and CHQ (r = −0.55) in the attenuated MPS I but not in the Hurler group. Conclusions: The association of somatic disease burden with physical quality of life and ability to carry out daily living skills suggests that the PSS will be useful in the measurement of disease and treatment effects in the attenuated MPS I group. Earlier treatment with transplant and differing parental expectations are possible explanations for its lack of association with other outcomes necessitating an adaptation for Hurler syndrome in the future.

AB - Objectives: We quantified medical signs and symptoms to construct the Physical Symptom Score (PSS) for use in research to assess somatic disease burden in mucopolysaccharidoses (MPS) to track disease and monitor treatments. We examined scoring reliability, its concurrent validity with other measures, and relationship to age in MPS type I. Methods: Fifty-four patients with MPS I (36 with Hurler syndrome treated with hematopoietic cell transplant and 18 with attenuated MPS I treated with enzyme replacement therapy), ages 5 to 18 years, were seen longitudinally over 5 years. The summation of frequency and severity of signs of specific organ involvement, surgeries, and hydrocephalus drawn from medical histories comprise the PSS. We examined relationship to age and to daily living skills (DLS) from the Vineland Adaptive Behavior Scale and physical quality of life from the Child Health Questionnaire (CHQ) for each group. Results: The PSS was associated with age in both groups, indicating increase in disease burden over time. The PSS was significantly negatively associated with DLS (r = −0.48) and CHQ (r = −0.55) in the attenuated MPS I but not in the Hurler group. Conclusions: The association of somatic disease burden with physical quality of life and ability to carry out daily living skills suggests that the PSS will be useful in the measurement of disease and treatment effects in the attenuated MPS I group. Earlier treatment with transplant and differing parental expectations are possible explanations for its lack of association with other outcomes necessitating an adaptation for Hurler syndrome in the future.

KW - Carpal tunnel syndrome

KW - Disease burden

KW - Enzyme replacement therapy

KW - Hematopoietic cell transplant

KW - Shunt placement

UR - http://www.scopus.com/inward/record.url?scp=84962409290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962409290&partnerID=8YFLogxK

U2 - 10.1007/8904_2015_485

DO - 10.1007/8904_2015_485

M3 - Other chapter contribution

T3 - JIMD Reports

SP - 61

EP - 68

BT - JIMD Reports

PB - Springer

ER -